XNASTNGX
Market cap330mUSD
Jan 21, Last price
3.08USD
1D
8.07%
1Q
-50.88%
IPO
-69.95%
Name
Tango Therapeutics Inc
Chart & Performance
P/E
—
P/S
9.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
37m
+46.93%
Net income
-102m
L-5.95%
CFO
-118m
L+8.16%
Earnings
Mar 17, 2025
Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 36,527 46.93% | 24,860 -32.89% | |||
Cost of revenue | 265,898 | 139,959 | |||
Unusual Expense (Income) | |||||
NOPBT | (229,371) | (115,099) | |||
NOPBT Margin | |||||
Operating Taxes | 134 | 54 | |||
Tax Rate | |||||
NOPAT | (229,505) | (115,153) | |||
Net income | (101,744) -5.95% | (108,176) 85.76% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 80,017 | 1,623 | |||
BB yield | -8.55% | -0.25% | |||
| Debt | |||||
Debt current | 2,082 | 1,770 | |||
Long-term debt | 75,758 | 80,492 | |||
Deferred revenue | 66,683 | 92,088 | |||
Other long-term liabilities | (15,033) | ||||
Net debt | (259,045) | (287,294) | |||
| Cash flow | |||||
Cash from operating activities | (117,982) | (109,080) | |||
CAPEX | (1,526) | (7,692) | |||
Cash from investing activities | 41,426 | 26,399 | |||
Cash from financing activities | 82,406 | 1,615 | |||
FCF | (225,151) | (166,837) | |||
| Balance | |||||
Cash | 336,885 | 366,133 | |||
Long term investments | 3,423 | ||||
Excess cash | 335,059 | 368,313 | |||
Stockholders' equity | (370,968) | (273,129) | |||
Invested Capital | 729,679 | 640,756 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 94,572 | 87,820 | |||
Price | 9.90 36.55% | 7.25 -33.73% | |||
Market cap | 936,267 47.05% | 636,695 -6.29% | |||
EV | 677,222 | 349,401 | |||
EBITDA | (226,956) | (113,491) | |||
EV/EBITDA | |||||
Interest | 2,949 | ||||
Interest/NOPBT | |||||